GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...
For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...
Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...
GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...
GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...
GSK PLC closed 18.56% short of its 52-week high of £18.24, which the company achieved on May 16th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback